ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. ABVC BioPharma, Inc. is one of them.

ABVC BioPharma, Inc. (NASDAQ:ABVC) tops our list for being one of the best penny stocks. It is a clinical-stage biopharmaceutical company developing botanically derived therapeutics for oncology, neurology, and ophthalmology. Its pipeline includes treatments for Major Depressive Disorder (MDD), ADHD, metastatic pancreatic cancer, myelodysplastic syndromes, and inflammatory bowel diseases.

The corporation reported strong financial growth, with assets rising 103% to $16.2 million in Q2 and shareholder equity up 18.7%, reflecting operational momentum. The business also said that it earned $350,000 in license revenue in July, which will be reported in the third quarter of 2025.

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s leading pipeline features ABV-1504, a potential safer alternative to Prozac for MDD, and PDC-1421, derived from Radix Polygala, targeting psychiatric disorders with fewer side effects. Phase II trials for both candidates have been completed, with global Phase III trials upcoming.

Its oncology pipeline is also progressing, with Phase II candidates such as BLI-1401 for metastatic pancreatic cancer and BLI-1301 for myelodysplastic syndromes generating investor interest.

While we acknowledge the potential of ABVC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.